RenovoRx Inc Dossier - Source-backed chat

RenovoRx Inc

RNXTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value $1.69median of 2 methodsbased on filings through 30 Jun 2026

Market Price $1.55Price as of 1 Oct 2026

Near fair valueIntrinsic value is 9% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $70M

Enterprise Value $60.7M

Shares Outstanding 44M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

RenovoRx is transitioning from a purely clinical-stage life sciences company to an early-revenue commercial entity, driven by its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform and the FDA-cleared RenovoCath device. The investment thesis centers on the dual-track value creation: near-term commercial ramp of RenovoCath as a stand-alone device for targeted oncology drug delivery, and the long-term blockbuster potential of its drug-device combination candidate (intra-arterial gemcitabine, or IAG) for locally advanced pancreatic cancer (LAPC). With Q1 2026 revenue showing explosive 136% quarter-over-quarter growth and the pivotal Phase III TIGeR-PaC trial nearing full enrollment, RenovoRx offers a highly asymmetric risk-reward profile at its current micro-cap valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$7.00

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

The TIGeR-PaC trial experiences enrollment delays or the final 2027 data fails to show a meaningful survival benefit, severely damaging the prospects of the IAG combination product. Commercial adoption of the stand-alone RenovoCath device stalls due to clinical inertia or reimbursement challenges, causing FY 2026 revenues to miss guidance. High cash burn forces the company to execute highly dilutive equity financings at depressed share prices, eroding shareholder value.

Base CaseCentral scenario

$6.0550%

RenovoRx successfully completes TIGeR-PaC enrollment in mid-2026, keeping the trial on track for a 2027 readout. Stand-alone RenovoCath commercial revenues meet the reiterated FY 2026 guidance of $3M to $4M, supported by the expansion of active commercial cancer centers from 16 toward the 48-center pipeline. The company utilizes its recently bolstered cash position ($12.4M as of Q1 2026) to fund operations through clinical milestones, though moderate dilutive capital raises may still be required in late 2026 or 2027 to support commercial scaling.

Bull CaseUpside scenario

$8.5030%

The Phase III TIGeR-PaC trial completes enrollment on schedule in 1H 2026, and final data in 2027 demonstrates a statistically significant overall survival benefit for IAG over standard-of-care systemic chemotherapy. Simultaneously, commercial adoption of the stand-alone RenovoCath device accelerates rapidly, exceeding the high end of FY 2026 revenue guidance ($4M) and expanding the active center footprint to over 48 locations. The company secures a lucrative out-licensing or co-development partnership for IAG, eliminating near-term dilution risks and driving the stock toward consensus analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Dual-Track Commercial and Clinical Strategy: Near-term revenue generation from the FDA-cleared stand-alone RenovoCath device helps offset clinical development costs and validates the TAMP platform.
Strong Commercial Momentum: Active commercial cancer centers grew from 5 in early 2025 to 16 as of May 2026, with a robust pipeline of 32 additional centers in onboarding stages.
Pivotal Phase III Milestones: The TIGeR-PaC trial has randomized over 100 of its 114-patient target, with enrollment completion expected in 1H 2026 and final data readout in 2027.
Improved Balance Sheet: A $10 million oversubscribed private placement in March 2026 extended the company's cash runway to support key clinical and commercial milestones.

Key Investment Risks

Clinical Trial Risk: The ultimate success of the company depends heavily on the final overall survival data from the TIGeR-PaC trial, which is not guaranteed to be positive.
Nascent Commercialization: Stand-alone device revenues are early-stage, volatile, and highly dependent on expanding physician adoption and procedural utilization.
Ongoing Loss Generation: The company is unprofitable, with an accumulated deficit of $61.4 million as of December 31, 2025, and will require additional capital before achieving cash-flow breakeven.
Micro-Cap Volatility and Dilution: As a micro-cap stock with a history of equity offerings, shareholders face ongoing risks of dilution and high share price volatility.

Thesis Invalidation Triggers

Failure to complete Phase III TIGeR-PaC trial enrollment by the end of 2026.
A negative recommendation or trial halt by the independent Data Monitoring Committee (DMC).
A significant drop in quarterly RenovoCath commercial revenues or a contraction in the number of active commercial cancer centers.
Severe cash depletion leading to a going-concern qualification in future SEC filings without access to capital.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.